上海青赛生物科技

Shanghai Qingsai Biological Technology is a Chinese biotechnology company dedicated to the research, development, and industrialization of innovative human vaccines. The company's lead product is a human rabies vaccine (Vero cell) produced using high-density cell culture technology, which has received marketing approval in China. Qingsai operates a modern manufacturing base in Shanghai's Fengxian District that adheres to international GMP standards. Its pipeline also includes a live attenuated varicella vaccine and other candidates targeting infectious diseases. The company is backed by prominent investors such as Hillhouse Capital and Legend Capital, positioning it as a significant player in the Chinese vaccine industry.